ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0711

SARS-CoV-2 Infection and Outcomes in Chronic Dialysis Patients

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Lacson, Eduardo K., Dialysis Clinic Inc, Nashville, Tennessee, United States
  • Aweh, Gideon N., Dialysis Clinic Inc, Nashville, Tennessee, United States
  • Ladik, Vladimir, Dialysis Clinic Inc, Nashville, Tennessee, United States
  • Manley, Harold J., Dialysis Clinic Inc, Nashville, Tennessee, United States
  • Stewart, Carol, Dialysis Clinic Inc, Nashville, Tennessee, United States
  • Johnson, Doug, Dialysis Clinic Inc, Nashville, Tennessee, United States
Background

The SARS-COV-2 pandemic (COVID) impacted ESRD patients on dialysis, categorized by the CDC as immunocompromised. We describe the characteristics and outcomes in patients treated by a non-profit dialysis provider.

Methods

From 2/17 to 5/29, 2020, Dialysis Clinic Inc. had identified 422 COVID+ patients from 90 clinics in 20 states. We compared their characteristics relative to the uninfected source clinic population (N=6,993) and tracked outcomes over the 15-week period.

Results

Comparative characteristics are shown in the table (*p<0.05). Hospitalization occurred in 295 (70%) with 75 deaths, 159 discharges and 61 still hospitalized. Ten patients died <30 days post-discharge. Another 11 deaths occurred in 116 non-hospitalized patients. Overall, 96 of 422 died (22.7%). While more black patients were infected, death rates were higher in white than black dialysis patients (31.5% vs. 18.8%, p=0.008).

Conclusion

Chronic dialysis patients with COVID have higher death rates than the general population. Infected patients tended to be older, with more comorbidity, particularly DM/CVD, and utilized respiratory inhalers/assistance. Group home residents were overrepresented with COVID while home dialysis patients were disproportionately spared.

Source: 90 DCI Clinics w/ 7,415 patientsCOVID+Non-COVID
N of Patients (%)422 (5.7%)6,993 (94.3%)
Age (years)65.3±13.3*62.1±14.9
% Male60.257.3
% White26.3*36.0
% Black56.9*46.5
% Other Race16.817.5
Vintage (days)1,692 ± 1,6991,668 ± 1,808
% Home Dialysis3.3*14.9
% CVC25.622.0
% Group Home38.9*6.4
% Albumin <3.5 g/dL19.2*14.5
# Comorbid Dis.3.3±1.9*3.0±1.9
% DM69.7*57.7
% AHD26.5*21.7
% CVA11.8*8.5
% HTN77.7*81.7
% Inhaler Use28.2*19.9
% Wheelchair3.6*1.8
% ADL Help0.9*0.3
BMI29.1 ± 7.428.8 ± 8.9

Note: % CHF, COPD, PVD, Smoking, ACEi-ARBs, Steroids, Flu/Pneumonia Vaccines similar.